Therapeutic targets for PD

As LRRK2 and alpha-synuclien are the two most important genes involved in the pathological manifestation of PD, these are the obvious two candidates which can be targeted for therapeutic purposes. The main approach would be to stop or slow the progression of the disease: and the best therapy possible would be complete reversal.